多发性硬化症患者中患者报告的残疾进展结果:基于结果的协议结果
Elizabeth C S Swart1, Samuel K Peasah1, Jacqueline Alderson2
1Value-Based Pharmacy Initiatives, UPMC Center for High-Value Health Care, Pittsburgh, PA.
Journal of managed care & specialty pharmacy
|October 29, 2024
概括
基于结果的协议 (OBA) 可以有效地跟踪多发性硬化症 (MS) 患者的结果. 这项研究发现,残疾进展发生在11%的患者中,服用干扰素β-1a的人的发病率高于服用二甲基烟酸相比.
科学领域:
- 卫生经济学 卫生经济学
- 药物经济学 药物经济学
- 现实世界的证据.
背景情况:
- 基于结果的协议 (OBA) 将药物支付与患者的健康结果联系起来,与转向以价值为基础的护理的转变保持一致.
- 多发性硬化症 (MS) 是OBA的关键领域,因为高药费和可用的治疗方法.
研究的目的:
- 通过使用现实世界的数据,评估针对多发性硬化症 (MS) 患者的基于结果的协议.
- 评估在OBA下服用干扰素β-1a或二甲基 fumarate的患者的残疾进展.
主要方法:
- 一个前性,现实世界的分析包括商业或医疗保险交易所成员与MS.
- 使用患者报告的结果 (PROs) 通过患者确定的疾病阶段 (PDDS) 工具来测量残疾进展.
- 在基线和随访 (90-180天) 收集了PDDS得分,以确定残疾进展.
主要成果:
- 在184名符合条件的患者中 (107人服用二甲基烟酸,77人服用干扰素β-1a),21人 (11%) 经历了确认的残疾进展.
- 双甲基 fumarate 队列:5.6% (6/107) 显示进展.
- 干扰素β-1a队列:19.5% (15/77) 呈现出进展.
结论:
- 患者报告的结果,如残疾进展,可以在基于结果的创新协议中成功运行.
- 该研究表明,使用OBA来监测MS治疗有效性的可行性.
相关概念视频
01:11Guidelines for Writing Outcome
3.8K
When developing expected outcomes for a patient care plan, the nurse should adhere to the following recommendations:
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
3.8K
01:19Multiple Sclerosis l: Introduction
20
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
20